CRY Share Price | Artivion, Inc. Stock Analysis & Recommendation

Q: How big is Artivion, Inc.?

Market Cap: As of Jun 18, Artivion, Inc. has a market capitalization of 1,315.53 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Artivion, Inc. reported net sales of 390.09 million and a net profit of -21.36 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 276.20 million and total assets of 789.10 million.

Q: What does Artivion, Inc. do?

Overview:Artivion, Inc. is a medical device manufacturer and processor engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.Financial Snapshot:Most recent Net Sales: 99 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 1,315.53 Million (Micro Cap)Key Metrics:Debt Equity: 0.96 Return on Equity: -4.00% Price to Book: 4.47 Contact Details:Address: 1655 Roberts Blvd NW, KENNESAW GA: 30144-3632 Tel: ['1 770 4193355', '1 646 9241769'] Fax: 1 770 4260031 Website: http://www.cryolife.com

Q: Is Artivion, Inc. overvalued or undervalued?

As of 17 February 2022, the valuation grade for Artivion, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its Price to Book Value of 4.35 and an EV to EBITDA ratio of 32.14, which are significantly higher than industry norms. Additionally, the company's Return on Capital Employed (ROCE) stands at a low 4.31%, while its Return on Equity (ROE) is negative at -4.00%, further highlighting its financial struggles.In comparison to peers, MiMedx Group, Inc. has a fair valuation with a P/E ratio of 33.09 and an EV to EBITDA of 18.90, while Embecta Corp. is also deemed risky with a P/E of 6.42 and an EV to EBITDA of 6.59. This stark contrast underscores Artivion's challenging position within the industry. Despite a strong year-to-date return of 44.67% compared to the S&P 500's 12.22%, the overall valuation metrics suggest that the stock may not be sustainable at its current price levels.

Q: Is Artivion, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Artivion, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating some positive momentum. However, the weekly and monthly RSI readings are bearish, suggesting potential weakness in price momentum. The Bollinger Bands show a bullish stance on the weekly and a mildly bullish stance on the monthly, supporting the overall mildly bullish trend. Daily moving averages are bullish, which is a positive sign for short-term traders. In terms of returns, Artivion has outperformed the S&P 500 year-to-date with a return of 44.67% compared to 12.22%, and over one year with a return of 65.64% compared to 17.14%. However, the recent one-week and one-month returns are negative at -2.25% and -3.48%, respectively, while the S&P 500 has gained 1.05% and 2.33% in the same periods. Overall, the current technical stance is mildly bullish, but with caution due to mixed signals from the RSI and recent performance.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

307.39 k

Shareholding (Dec 2025)

FII

5.98%

Held by 92 FIIs

DII

47.74%

Held by 52 DIIs

Promoter

0.00%

How big is Artivion, Inc.?

22-Jun-2025

As of Jun 18, Artivion, Inc. has a market capitalization of 1,315.53 million, classifying it as a Micro Cap company, with net sales of 390.09 million and a net profit of -21.36 million over the latest four quarters.

View full answer

What does Artivion, Inc. do?

22-Jun-2025

Artivion, Inc. is a medical device manufacturer specializing in implantable human tissues for cardiac surgeries, classified as a Micro Cap company with a market cap of approximately $1.32 billion. As of March 2025, it reported net sales of $99 million and a net profit of -$1 million.

View full answer

Who are in the management team of Artivion, Inc.?

22-Jun-2025

As of March 2022, the management team of Artivion, Inc. includes Chairman and CEO James Mackin, Presiding Independent Director Ronald McCall, and independent directors Thomas Ackerman, Daniel Bevevino, Marna Borgstrom, and James Bullock. This team provides governance and strategic direction for the company.

View full answer

Is Artivion, Inc. overvalued or undervalued?

20-Sep-2025

As of February 17, 2022, Artivion, Inc. has shifted from an attractive to a risky valuation due to overvaluation indicators like a Price to Book Value of 4.35 and an EV to EBITDA ratio of 32.14, coupled with low ROCE of 4.31% and negative ROE of -4.00%, despite a strong year-to-date return of 44.67%.

View full answer

Is Artivion, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Artivion, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, but mixed signals from RSI and recent negative returns suggest caution.

View full answer

Compare Artivion, Inc. with Similar Stocks

Nevro Corp.Atrion Corp.Cytek Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Operating Profit of 58.5%, the company declared Very Positive results in Jun 25

The company has declared positive results in Jan 70 after 2 consecutive negative quarters
OPERATING CASH FLOW(Y) Highest at USD 19.66 MM
INTEREST COVERAGE RATIO(Q) Highest at 227.26
RAW MATERIAL COST(Y) Fallen by -1.86% (YoY)

Consistent Returns over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,846 Million (Small Cap)

P/E

93.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.35

Return on Equity

4.45%

Price to Book

4.12

Revenue and Profits:

Net Sales:

116 Million

(Quarterly Results - Dec 2025)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.54%

6 Months

-5.46%

1 Year

55.06%

2 Years

89.37%

3 Years

205.06%

4 Years

83.42%

5 Years

59.15%

Artivion, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.75%

EBIT Growth (5y)

71.75%

EBIT to Interest (avg)

0.71

Debt to EBITDA (avg)

7.70

Net Debt to Equity (avg)

0.96

Sales to Capital Employed (avg)

0.62

Tax Ratio

5.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

93.74%

ROCE (avg)

3.37%

ROE (avg)

1.46%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.12

EV to EBIT

50.02

EV to EBITDA

32.05

EV to Capital Employed

3.31

EV to Sales

4.54

PEG Ratio

0.43

Dividend Yield

ROCE (Latest)

6.62%

ROE (Latest)

4.45%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 64 Schemes (46.21%)

Foreign Institutions

Held by 92 Foreign Institutions (5.98%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 2.29% vs 0.35% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -63.08% vs 400.00% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "116.00",
          "val2": "113.40",
          "chgp": "2.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.20",
          "val2": "17.40",
          "chgp": "4.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.50",
          "val2": "6.10",
          "chgp": "-9.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.40",
          "val2": "-2.70",
          "chgp": "-137.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.40",
          "val2": "6.50",
          "chgp": "-63.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "107.60%",
          "val2": "102.60%",
          "chgp": "0.50%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 13.59% vs 9.75% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 173.68% vs 56.54% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "441.30",
          "val2": "388.50",
          "chgp": "13.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "56.60",
          "val2": "51.70",
          "chgp": "9.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "26.70",
          "val2": "34.40",
          "chgp": "-22.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.70",
          "val2": "2.40",
          "chgp": "-629.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "9.80",
          "val2": "-13.30",
          "chgp": "173.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "77.50%",
          "val2": "70.70%",
          "chgp": "0.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

116.00

113.40

2.29%

Operating Profit (PBDIT) excl Other Income

18.20

17.40

4.60%

Interest

5.50

6.10

-9.84%

Exceptional Items

-6.40

-2.70

-137.04%

Consolidate Net Profit

2.40

6.50

-63.08%

Operating Profit Margin (Excl OI)

107.60%

102.60%

0.50%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 2.29% vs 0.35% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -63.08% vs 400.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

441.30

388.50

13.59%

Operating Profit (PBDIT) excl Other Income

56.60

51.70

9.48%

Interest

26.70

34.40

-22.38%

Exceptional Items

-12.70

2.40

-629.17%

Consolidate Net Profit

9.80

-13.30

173.68%

Operating Profit Margin (Excl OI)

77.50%

70.70%

0.68%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 13.59% vs 9.75% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 173.68% vs 56.54% in Dec 2024

All Annual Results

Company CV

About Artivion, Inc.

Artivion, Inc.

Pharmaceuticals & Biotechnology

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.

Company Coordinates

Company Details

1655 Roberts Blvd NW , KENNESAW GA : 30144-3632

Tel: 1 770 41933551 646 9241769

http://www.cryolife.com

Registrar Details